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Detecting and treating Alzheimer’s disease, before cognitive deﬁcits occur, has become the health challenge of our time. The earliest
known event in Alzheimer’s disease is rising amyloid-b. Previous studies have suggested that effects on synaptic transmission may
precede plaque deposition. Here we report how relative levels of different soluble amyloid-b peptides in hippocampus, preceding
plaque deposition, relate to synaptic and genomic changes. Immunoprecipitation-mass spectrometry was used to measure the early
rise of different amyloid-b peptides in a mouse model of increasing amyloid-b (‘TASTPM’, transgenic for familial Alzheimer’s
disease genes APP/PSEN1). In the third postnatal week, several amyloid-b peptides were above the limit of detection, including
amyloid-b40, amyloid-b38 and amyloid-b42 with an intensity ratio of 6:3:2, respectively. By 2 months amyloid-b levels had only
increased by 50% and although the ratio of the different peptides remained constant, the ﬁrst changes in synaptic currents,
compared to wild-type mice could be detected with patch-clamp recordings. Between 2 and 4 months old, levels of amyloid-b40
rose by 7-fold, but amyloid-b42 rose by 25-fold, increasing the amyloid-b42:amyloid-b40 ratio to 1:1. Only at 4 months did plaque
deposition become detectable and only in some mice; however, synaptic changes were evident in all hippocampal ﬁelds. These
changes included increased glutamate release probability (P50.001, n = 7–9; consistent with the proposed physiological effect of
amyloid-b) and loss of spontaneous action potential-mediated activity in the cornu ammonis 1 (CA1) and dentate gyrus regions of
the hippocampus (P5 0.001, n = 7). Hence synaptic changes occur when the amyloid-b levels and amyloid-b42:amyloid-b40 ratio
are still low compared to those necessary for plaque deposition. Genome-wide microarray analysis revealed changes in gene
expression at 2–4 months including synaptic genes being strongly affected but often showing signiﬁcant changes only by 4
months. We thus demonstrate that, in a mouse model of rising amyloid-b, the initial deposition of plaques does not occur until
several months after the ﬁrst amyloid-b becomes detectable but coincides with a rapid acceleration in the rise of amyloid-b levels
and the amyloid-b42:amyloid-b40 ratio. Prior to acceleration, however, there is already a pronounced synaptic dysfunction, reﬂected
as changes in synaptic transmission and altered gene expression, indicating that restoring synaptic function early in the disease
progression may represent the earliest possible target for intervention in the onset of Alzheimer’s disease.
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Introduction
Alzheimer’s disease is only diagnosed after cognitive deﬁcits
become evident late in the disease, by which stage extensive
synaptic and neuronal degeneration have occurred (Fox et al.,
1996). Thus treatments that avoid or delay these irreversible
consequences by targeting the earliest changes are urgently
needed. Mice transgenic for familial Alzheimer’s disease
genes do not develop tau tangles and often lack extensive
neuronal loss or learning deﬁcits. They are consequently not
good models for the full course of Alzheimer’s disease
(Howlett and Richardson, 2009) making the poor translation
from animal models to treatments for advanced disease states
unsurprising. However, transgenic mice are appropriate
models for studying the effects of the initial rise of amyloid-
b in the brain, which is likely one of the earliest events in all
forms of the disease, regardless of the trigger initiating that
rise (Jack et al., 2013). Note that the initial rise of different
soluble amyloid-b species and the development of plaques do
not correlate with neurodegenerative changes, but rather
precede this advanced stage of the disease. This period of
disease progression before diagnosis lasts for decades
representing a valuable window for therapeutic intervention
before irreversible neurodegenerative changes and conse-
quent cognitive loss occur (see Lesne et al., 2013 for a
review). In this study, we investigate the changes likely to be
occurring at the earliest phases of Alzheimer’s disease in
TASTPM mice as levels of amyloid-b ﬁrst rise due to
expression of transgenic mutant genes that clinically result
in familial Alzheimer’s disease (APPSwe/PSEN1M146V;
Howlett et al., 2004). Changes preceding plaques (although
without measurement of soluble amyloid-b peptides) have
previously been reported in mouse models (Jacobsen et al.,
2006; Palop et al., 2007; D’Amelio et al., 2011). Recently
Tozzi et al. (2015) also reported changes in long-term potenti-
ation and excitatory synaptic currents preceding plaque de-
position in double APP transgenic mice, although another
study found no change in the same mice at this stage (Jolas
et al., 2002).
The TASTPM phenotype develops gradually, but quickly
enough to make it practical for detecting early changes and
for combining a multidisciplinary array of information
(Howlett et al., 2008). The complicating factors of single
housing, generally used in past studies of APP transgenic
mice, is avoided by using enriched environments, in which
the mice can be successfully group-housed despite an
aggressive phenotype. Single housing is a model for schizo-
phrenia (Gresack et al., 2010) and thus adds a potentially
confounding variable, independent of amyloid-b accumula-
tion. As environmental enrichment has been reported to
rescue the phenotype of some transgenic animals
(Hannan, 2014), we also conﬁrm the histological status
of TASTPM mice under the conditions of this study.
We concentrate on changes in fast synaptic transmission
and differential gene expression in hippocampus of
TASTPM mice, from the third week of life when we can
barely detect amyloid-b, through to 4 months when plaques
are ﬁrst detected. As the release of amyloid-b occurs from
glutamatergic neurons in an activity-dependent fashion
(Kamenetz et al., 2003), changes in spontaneous activity
of excitatory transmission in the hippocampus might inﬂu-
ence the amyloid-b levels (see Stargardt et al., 2015 for
review). We thus study the spontaneous glutamatergic
activity as well as investigating whether we can detect
increased release probability, this being one of the putative
physiological effects of released amyloid-b (Abramov et al.,
2009) that could link the physiological and pathophysio-
logical outcomes of amyloid-b release. Our recent genome-
wide microarray analysis of gene expression in these mice
(Matarin et al., 2015) has allowed network analysis of gene
expression that reveals primary changes in synaptic genes
and a range of possible drug targets.
Materials and methods
See supplementary material for further details of materials and
methods used.
Animals
All experiments were performed in agreement with the
Animals (Scientiﬁc Procedures) Act 1986, with local ethical
approval and in agreement with the GlaxoSmithKline state-
ment on use of animals. Unless otherwise stated, male hetero-
zygous TASTPM mice, bred by crossing male homozygous
TASTPM (APPSwe/PSEN1M146V; Howlett et al., 2004)
with female C57Bl/6j were compared to age-matched, non-
littermate male C57Bl/6j mice. Mice were group-housed in
enriched environments to circumvent the aggressive TASTPM
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phenotype. TASTPM and wild-type mice were bred and
housed in the same room under the same conditions at
University College London.
Acute hippocampal brain slice
preparation
Acute brain slices were prepared using standard methods
(Edwards et al., 1989) adapted for mice (Parsley et al.,
2007). Details differing from these methods are described
brieﬂy. Following decapitation the brain was rapidly removed
into ice-cold dissection artiﬁcial CSF [containing (in mM):
125 NaCl, 2.4 KCl, 26 NaHCO3, 1.4 NaH2PO4, 20
D-glucose, 3 MgCl2, 0.5 CaCl2, 315 mOsm/l, pH 7.4]
and hippocampal slices with attached entorhinal cortex
(400mm) were cut transverse to the long axis of the hippocam-
pus. At 5-min intervals, slices were transferred through a series
of oxygenated chambers (95% O2/5% CO2) containing dissec-
tion artiﬁcial CSF (21–24C) to artiﬁcial CSF (36C) with
consecutive Ca2+ and Mg2+ ion concentrations (in mM):
(i) 1 Mg2+ , 0.5 Ca2+ ; (ii) 1 Mg2+ , 1 Ca2+ ; and (iii)
1Mg2+ , 2 Ca2+ . In the ﬁnal chamber, containing recording
artiﬁcial CSF (as for dissection artiﬁcial CSF but with 2mM
Ca2+ and 1mM Mg2+ ), slices were allowed to return to room
temperature and recover for at least 40min before
experimentation.
Electrophysiological recordings
in brain slices
Patch clamp recordings were made at room temperature
(21–24C) using CsCl-based intracellular solution. For record-
ing ﬁeld potentials, brain slices were submerged in a heated
(30  1C) recording chamber, superfused with artiﬁcial CSF.
Responses were evoked by applying stimuli (100 ms) using an
artiﬁcial CSF-ﬁlled glass electrode placed as indicated in
Supplementary Fig. 1. Signals were ﬁltered at 10 kHz and
subsequently at 2 kHz during digitization (10 kHz). WinEDR
or WinWCP (Strathclyde Electrophysiology Software) were
used for detection and measurement of events. Criteria for
detection of spontaneous and miniature events were to
remain over a 3 pA threshold for 42ms; rise time was
53ms and faster than the decay. All analyses in this and all
subsequent sections were carried out blind to genotype. To
ensure that changes in frequency were not the result of
decreased amplitude resulting in loss of events into the baseline
noise, control experiments were carried out to assess the effects
of decreased amplitude by decreasing the holding voltage to a
level at which the mean amplitude in slices from wild-type
mice was equivalent to that seen in TASPTM mice and the
frequency was assessed (Supplementary Fig. 2).
Hippocampal histology
Sections were stained using standard immunohistological
techniques (Supplementary material). Primary amyloid-b40 or
amyloid-b42 (1:300, Invitrogen) antibody was incubated
overnight. Sections were then incubated in goat anti-rabbit
secondary antibody (1:600, Jackson ImmunoResearch).
For estimating neuronal loss, sections were incubated in
0.2% cresyl violet.
In each section cut across the hemisphere, the entire area of
the hippocampal regions contained within that section was
imaged by collaging tiled adjacent subregions. To represent
data from the entire hippocampus multiple sections were
imaged at different levels through the structure using an
EVOS FL Auto microscope (Life Technologies). For quantiﬁ-
cation, a 480  360mm region was deﬁned in CA1, CA3 and
dentate gyrus of each section. The image was converted to
8 bit, an equivalent threshold applied and each plaque traced
and measured in ImageJ (NIH). For estimation of neuronal
loss, neurons in each region were manually counted using
ImageJ.
Immunoprecipitation–mass
spectrometry
Immunoprecipitation–mass spectrometry was performed as
described in Portelius et al. (2010) with the following adap-
tions for mouse: for immunoprecipitation, 4mg of the amyloid-
b-speciﬁc antibodies 6E10 and 4G8 were separately added to
25 ml Dynabeads M-280 (Dynal) sheep anti-mouse according
to the manufacturer’s product description. Data were averaged
from both hemispheres of each animal and then mean and
standard error of the mean (SEM) calculated from three
animals per age group.
RNA extraction, microarrays and
gene–network analysis
All procedures were completed as described in Matarin et al.,
(2015) and genome-wide data can be found at www.mouseac.
org or at http://www.ncbi.nlm.nih.gov/geo (accession
GSE64398). Genome-wide microarray data were conﬁrmed
by quantitative PCR on hippocampal RNA isolated from 4-
month-old homozygous TASTPM and wild-type counterparts.
Statistical analyses
All sample sizes indicate number of animals. Where more than
one sample was taken from an individual animal, data
were pooled and mean SEM calculated from the individual
animal means. Statistical analyses were performed using
Prism (GraphPad) as indicated.
Results
Assessment of amyloid-b load
We ﬁrst assessed the plaque development under the condi-
tions of this study, i.e. environmentally enriched group-
housing (Fig. 1). At 2 months of age no amyloid-b plaques
were detected in the eight TASTPM mice examined; by
4 months sparse plaques were detected in the hippocampi
of ﬁve of eight TASTPM mice examined. These plaques
were rare and small (51200mm2), occurring most fre-
quently in the CA1 region of the hippocampus and the
subiculum (Fig. 1A–C) but not present in every section
sampled. Note that, although quantiﬁcation was carried
out on regions of interest at different levels through the
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Figure 1 Amyloid-b, hippocampal plaque loads and neuronal counts in 4-month-old TASTPM mice. (A) Representative images of
the TASTPM hippocampus immunostained with amyloid-b40 antibody showing spatial distribution of amyloid-b plaques. Boxes define regions used
for quantification and plaque frequency distribution analysis. Scale bar = 200 mm. (B) Representative images of plaques observed in CA1, dentate
gyrus (DG) and CA3 detected with antibodies to amyloid-b40 and amyloid-b42. Scale bar = 25mm. (C) Size-frequency distribution of all amyloid-b
plaques counted across all areas of hippocampi from TASTPM (plaques were detected in five of eight mice examined). All plaques were relatively
small, with the majority of plaques at 4 months 5500 mm2. (D–F) Representative examples of immunoprecipitation-mass spectra from TASTPM
at ages indicated (n = 3 per age and genotype). Note the different y-axes between F and D, (G) Ratios of amyloid-b isoforms (normalized to
amyloid-b40 at each age). (H) Sections from 4-month-old wild-type and TASTPM mice stained with cresyl violet. Scale bar = 50 mm. (I) No
significant neuronal loss is detected at 4 months old in either CA1 or CA3 regions of the TASTPM hippocampus, t-test P4 0.05. Data repre-
sented as mean  SEM in a 480  360 mm area, n = 3 animals wild-type; n = 4 animals TASTPM; the dentate gyrus was too dense for quanti-
fication. WT = wild-type.
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hippocampus, within each section, the whole hippocampal
region was imaged. Hence plaques outside the region of
interest were also detected in the qualitative analysis of
whether there were any detectable plaques.
Having established that the ﬁrst plaques in TASTPM
mice appear by 4 months, immunoprecipitation-mass spec-
trometry was used to investigate relative levels of different
amyloid-b peptides at this and earlier ages before appear-
ance of plaques.
At 2–3 weeks old, amyloid-b could already be detected in
the hippocampus of TASTPM mice, with amyloid-
b38:amyloid-b40:amyloid-b42 ratios of approximately 3:6:2
(Fig. 1D and G, n = 3 TASTPM mice per age). Amyloid-b4-
40 and amyloid-b1-37 were also detected in all samples,
albeit just above the limit of detection (in the range of
250 pg/ml) and at about half the level of amyloid-b42.
By 2 months, the peptides detected and their ratios were
similar but the levels were 50% higher (Fig. 1E and G).
Note that at this stage there were no detectable plaques and
hence this presumably largely represents soluble amyloid-b.
By 4-months-old, when plaques were ﬁrst detected, the
situation had changed considerably. At this stage the levels
increased further but the ratios of different peptides were
also greatly altered. Only small increases (0–60%) in the
shorter peptides were identiﬁed compared to 2 months but
amyloid-b40 increased 47-fold and amyloid-b42 by
25-fold, reaching the same levels or even higher than
amyloid-b40 (Fig. 1F and G). Some new peptides also
reached detectable levels at this age with amyloid-b4-40,
amyloid-b1-39 and amyloid-b1-43 also showing similar
levels to the shorter peptides above, being 1–3% of the
level of amyloid-b42. Hence the deposition of plaques coin-
cided with a rapid change in both peptide levels and ratios,
including a considerable rise in the ratio of amyloid-
b42:amyloid-b40. We thus concentrated on this period of
rapid change to investigate under what conditions
changes in synaptic transmission became evident. No amyl-
oid-b peptides could be detected in the wild-type mice at
any age.
Despite the changes in amyloid-b levels and ratios, neur-
onal density remained unchanged at 4 months in both the
CA1 and CA3 regions of TASTPM compared to wild-type
(Fig. 1H and I).
Synaptic transmission is changed
in all hippocampal regions before
amyloid-b deposits first become
evident
CA1 region
Spontaneous and miniature excitatory synaptic activity
AMPA (-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid) receptor-mediated synaptic currents were isolated
using patch-clamp recordings of hippocampal CA1 pyram-
idal neurons in the presence of the GABAA receptor
antagonist gabazine (6 mM). At 4 months old, the frequency
of spontaneous excitatory postsynaptic currents (EPSCs) in
TASTPM was substantially lower than in wild-type mice
(Fig. 2A and B; P5 0.0001).
In a subset of slices (from three wild-type and two
TASTPM mice), application of the AMPA receptor antag-
onist CNQX (6-cyano-7-nitroquinoxaline-2,3-dione;
20 mM) and the NMDA receptor antagonist DL-AP5
(2-amino-5-phosphonopentanoic acid; 50 mM) in the pres-
ence of gabazine abolished all spontaneous currents,
conﬁrming their glutamatergic origin (data not shown).
In other slices, to isolate miniature EPSCs, the sodium
channel blocker tetrodotoxin (1 mM) was added to the
gabazine solution. As expected, tetrodotoxin decreased
the frequency of EPSCs by 3-fold in slices from
4-month-old wild-type mice (Fig. 2B). In contrast, tetrodo-
toxin had no signiﬁcant effect on EPSCs in slices from
TASTPM mice (Fig. 2B).
Considering the rapid rise in amyloid-b levels and amyl-
oid-b42:amyloid-b40 ratios at 4 months, we went on to in-
vestigate whether this represented the ﬁrst changes in
synaptic transmission, suggesting a causal link. However,
the change in spontaneous EPSCs was similar when the
experiment was repeated at 2 months, at which stage no
plaques could be found and overall amyloid-b levels and
amyloid-b42:amyloid-b40 ratio was 3-fold lower (Fig. 2B).
Thus, from 2 months onwards in TASTPM mice, there was
an almost complete absence of spontaneous action poten-
tial-dependent EPSCs.
Consistent with this, the median amplitude of spontan-
eous EPSCs in 2- and 4-month-old TASTPM mice was the
same as for miniature EPSCs; while in cells from wild-type
mice, spontaneous EPSCs showed greater median ampli-
tudes by 20% (wild-type: 13.2  0.6 pA, n = 7 animals;
TASTPM 10.7  0.9 pA, n = 7 animals; P50.05).
CA1 pyramidal cells receive excitatory inputs both from
CA3 neurons via Schaffer collaterals and from entorhinal
cortex. However, when the Schaffer collaterals were cut in
slices from wild-type mice, the frequency of spontaneous
EPSCs decreased to approximately the same level as mini-
ature EPSCs suggesting that most of the spontaneous activ-
ity originates from the CA3 cells (Supplementary Fig. 2)
and hence it is this activity that is lost in TASTPM mice.
Considering that we had already established that there was
no loss of CA3 neurons (Fig. 1), we went on to investigate
whether Schaffer collaterals remained excitable and to com-
pare them to entorhinal inputs.
Minimal evoked transmission from different input pathways
In slices from 4-month-old mice, EPSCs were evoked by
placing an extracellular glass electrode either in the
Schaffer collaterals in stratum radiatum or amongst the
entorhinal inputs in the stratum lacunosum moleculare,
while making a whole-cell patch clamp recording from a
CA1 pyramidal neuron. Once the minimal stimulus voltage
was established, paired-pulse stimuli were applied at inter-
vals between 25 and 200ms. AMPA or NMDA receptor-
1996 | BRAIN 2015: 138; 1992–2004 D. M. Cummings et al.
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Figure 2 Absence of spontaneous EPSCs in TASTPM CA1 pyramidal neurons (4-months-old unless otherwise indicated). (A)
Top: Example traces (Vhold = 70 mV) showing spontaneous EPSCs from 4 m TASTPM and age-matched wild-type mice. Asterisks indicate
confirmed EPSCs. Bottom: Example miniature EPSCs from 4 m TASTPM and wild-type mice. (B) Mean frequency of spontaneous (s) EPSCs and
miniature (m) EPSCs. Sample sizes (WT/TASTPM): spontaneous EPSCs: 2 m: 11/7; 4 m: 7/7; miniature EPSCs: 2 m: 8/5; 4 m: 8/8 animals. Two-way
ANOVA revealed a significant main effect of genotype (2 m: P5 0.05; 4 m: P5 0.001) and tetrodotoxin (2 m: P5 0.05; 4 m: P5 0.001). (C)
Example evoked EPSCs from CA3–CA1 synapses at 4 m. (D) Paired-pulse ratios (EPSC2amplitude/EPSC1amplitude) were lower in TASTPM (n = 8)
than wild-type (n = 6) mice at CA3–CA1 synapses. Two-way ANOVA: main effect of interval (P5 0.0001); genotype (P5 0.01). Post hoc sig-
nificance as indicated. Inset: The proportion of stimuli that failed to evoke a successful EPSC was lower in TASTPM than wild-type. (E) Entorhinal
cortical-CA1 synapses (temporoammonic pathway) showed no difference in paired-pulse ratios between wild-type (n = 5) and TASTPM (n = 6).
(F) Paired-pulse ratios at CA3–CA1 synapses in 2-month-old wild-type (n = 5) and TASTPM (n = 5) animals. Two-way ANOVA revealed significant
main effects of genotype (P = 0.016), and interval (P5 0.0001). (G) First unitary EPSCs at Schaffer collateral (CA3-CA1) synapses are larger in
slices from TASTPM (n = 6) than wild-type (n = 8); (P5 0.0001). (H) In contrast, at temporoammonic synapses, the amplitudes of the first unitary
EPSCs were statistically identical between TASTPM (n = 6) and wild-type mice (n = 5). (I) Paired-pulse ratios of pharmacologically isolated NMDA
receptor-mediated EPSCs at CA3–CA1 synapses were lower in TASTPM (n = 7) than wild-type mice (n = 6). Two-way ANOVA revealed sig-
nificant main effects of genotype (P = 0.01) and interval (P5 0.0001). In all panels significance by Sidak post hoc analysis indicated as *P5 0.05,
**P5 0.01, ***P5 0.001, ****P5 0.0001. WT = wild-type.
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mediated currents were isolated by including appropriate
antagonists in the bath solution (as above) and altering
the Mg2+ concentration of the artiﬁcial CSF. Note that
the evoked EPSCs from wild-type mice are of similar amp-
litude to spontaneous EPSCs, consistent with stimulation of
single or very few axons.
CA1 synapses from both Schaffer collaterals and entorh-
inal afferents in wild-type mice show paired-pulse facilita-
tion (Fig. 2C), with the second EPSC in the pair having an
amplitude of 2.5 times the amplitude of the ﬁrst at the
25ms interval, irrespective of the pathway stimulated
(Fig. 2D and E). As expected, as the interval is increased,
the interaction between the stimuli decreases, resulting
eventually in a paired-pulse ratio close to one. At
Schaffer collateral-CA1 synapses, the amplitude of the
ﬁrst EPSC in the pair was signiﬁcantly greater in slices
from TASTPM mice than from wild-type mice (Fig. 2G),
demonstrated by the shift to the right in the amplitude
cumulative probability plot. This could be explained by
an increase in glutamate release probability, as the
paired-pulse ratio was considerably lower in slices from
TASTPM than from wild-type mice at the shortest intervals
(Fig. 2D) and there were signiﬁcantly fewer failures to
release glutamate (Fig. 2D inset). These effects were speciﬁc
to the Schaffer collaterals, as stimulation of the axons from
entorhinal cortex showed no difference between wild-type
and TASTPM mice in amplitude of evoked EPSCs in
CA1 pyramidal neurons, or in paired-pulse ratios (Fig. 2E
and H).
In combination these data suggest that, although the
Schaffer collaterals do not ﬁre action potentials spontan-
eously in TASTPM mice, they are nevertheless intact and
can be activated by extracellular stimulation. Moreover,
when activated, CA3 axons from TASTPM mice release
neurotransmitter more readily than CA3 axons from
wild-type mice, reﬂecting a higher probability of glutamate
release. However, the change in release probability is
speciﬁc to the Schaffer collaterals and does not occur in
the entorhinal pathway.
Isolated NMDA receptor-mediated currents evoked by
Schaffer collateral stimulation were then recorded in
nominally Mg2+-free artiﬁcial CSF with the AMPA
receptor antagonist NBQX (2,3-Dioxo-6-nitro-1,2,3,4-
tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt;
10mM) and GABAA receptor antagonist, 6mM gabazine.
Consistent with the changes in AMPA receptor-mediated
EPSCs described above, paired-pulse ratios of NMDA recep-
tor-mediated EPSCs were lower in TASTPM than wild-type
mice, consistent with a presynaptic change in probability of
glutamate release (Fig. 2I).
Similar to the spontaneous activity, the paired-pulse ratio of
AMPA receptor-mediated EPSCs was tested at 2 months and a
signiﬁcant decrease was already evident (Fig. 2F).
CA3 region
Given the substantial presynaptic changes observed at CA3-
CA1 synapses, we next studied synaptic transmission in the
CA3 region. In the slices used in this study, in many cases
CA3 neurons tended to be too fragile for patch clamp
recording in both wild-type and transgenic mice. Thus, to
avoid changing the slice angle or using a selected popula-
tion of cells, we used extracellular ﬁeld recording for this
section of the study. CA3 neurons receive inputs from
different sources and the speciﬁc pathways can be evoked
separately by appropriate electrode placement. Possibly due
to the angle of the slice (optimized for CA1 recording) or
the very proximal location of the synapses in relation to the
cell soma (Brown and Johnston, 1983), especially in mouse,
we were unable to evoke clear ﬁeld responses when stimu-
lating the mossy ﬁbre pathway in our preparation. We
could, however, identify CA3–CA3 synapses and perforant
path–CA3 synapses, the latter originating in entorhinal
cortex.
In both pathways, although there was no signiﬁcant
difference in input/output relationships between genotype,
the TASTPM responses tended to be smaller than wild-type
(Fig. 3A and B). Moreover, in contrast to the CA1 region,
TASTPM mice displayed greater paired-pulse ratios than
wild-type (Fig. 3C and D). Two-way ANOVA revealed a
signiﬁcant main effect of both genotype (P5 0.05) and
interval (P50.0001); post hoc multiple comparisons
revealed signiﬁcant differences between wild-type and
TASTPM at both 25 and 50ms interpulse intervals.
The increase in paired-pulse ratio suggests a decreased
probability of glutamate release in both pathways and,
although the trend to a difference in input/output relation-
ship did not reach statistical signiﬁcance, this would be
consistent with a decrease in activity in the CA3 region,
which would likely result in a decrease in spontaneous
activity in the CA1 region, as reported above. Note, how-
ever, that the interpretation of this result should be treated
with some caution, as the conditions of a ﬁeld recording in
the absence of antagonists is somewhat different from the
situation of recording minimal responses from a single
neuron in the presence of a GABAA antagonist and may
have been inﬂuenced by unassessed factors in the synaptic
network.
Dentate gyrus
Mossy ﬁbres arise from dentate gyrus granule cells and so
we made patch clamp recordings of spontaneous synaptic
currents from these cells. While no changes were observed
in the frequency of spontaneous EPSCs or miniature EPSCs
at 2 months (Fig. 3E), the frequency of spontaneous EPSCs
was lower in cells from 4-month-old TASTPM mice than
wild-type (Fig. 3F). However, unlike in the CA1 region, in
the presence of tetrodotoxin (1 mM), the frequency of mini-
ature EPSCs was lower in TASTPM than wild-type mice
(Fig. 4F) and miniature EPSC amplitude also tended to be
lower, although this did not reach signiﬁcance
(8.9  0.7 pA, n = 7 animals and 7.4  0.3 pA, n = 8
animals, respectively; P = 0.06). This suggests a change in
postsynaptic receptors as well as release probability or
number of release sites of the perforant path axons.
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In summary, at 4 months old, excitatory transmission
was affected in all parts of the hippocampal tri-synaptic
circuit, with the frequency of spontaneous EPSCs being
decreased throughout, as measured in the CA1 and dentate
gyrus and as inferred from release probability or activity of
the incoming pathways in the CA3 region. No neuronal
loss was evident. Release probability of inputs onto CA1
pyramidal cells from the CA3 terminals was increased, as
was release probability from the perforant path onto
dentate granule cells. However, in contrast, the release
probability of at least two of the pathways impinging on
CA3 cells seemed to be decreased, suggesting that this
could be a major factor in the decreased spontaneous
activity seen in the CA1 region. Although the changes
measured in the dentate gyrus were only seen at
4 months, the changes in the CA1 region did not depend
on the high levels of amyloid-b detected at 4 months, nor
on a high ratio of amyloid-b42:amyloid-b40 as similar
changes were seen already at 2 months of age.
Changes in synaptic transmission
precede sharp rises in amyloid-b and
plaque deposition but are not
developmental
Considering the large synaptic changes seen in 2-month-old
TASTPM mice in the CA1 region, despite the lack of
plaque deposition, one possibility was that the effects
seen were developmental, due to the position of transgene
insertion or overexpression of the APP and/or PSEN1,
independent of increasing amyloid-b levels. We thus
tested whether we could detect synaptic changes in the
CA1 region in mice at 2-3 weeks old. No changes were
detectable in spontaneous, miniature or evoked EPSCs
(Fig. 4). We also measured synaptic transmission in slices
from TAS10 mice that express the APP transgene alone and
found no signiﬁcant changes up to 4 months
(Supplementary Fig. 3). Hence we conclude that the
changes detected at 2 months in TASTPM mice are some
of the earliest changes occurring and result from the slowly
increasing levels of soluble amyloid-b that are insufﬁcient,
or have not been present for long enough, to have measure-
able effects at 2–3 weeks.
Figure 3 Synaptic transmission within the TASTPM CA3
and dentate gyrus. (A) Perforant path (PP)-CA3 synapses input-
output relationship. (B) CA3-CA3 recurrent synapses input-output
relationship. (C) Paired-pulse ratio profile at PP-CA3 synapses. (D)
Paired-pulse ratio profile at CA3–CA3 synapses. Sample sizes (wild-
type/TASTPM) A and C: 7/8; B and D: 7/7. (E) Spontaneous EPSC
frequencies in 2 month dentate gyrus. Sample sizes (wild-type/
TASTPM): spontaneous EPSCs: 10/7; miniature EPSCs 7/8 animals.
(F) Miniature EPSC frequencies in 2 month dentate gyrus. Sample
sizes (wild-type/TASTPM): spontaneous EPSCs: 9/9; miniature
EPSCs 6/8 animals. Two-way ANOVA: main effects of genotype
(P5 0.0001) and tetrodotoxin (P5 0.0001).
Figure 4 Normal synaptic transmission at TASTPM CA3-
CA1 synapses at 2 weeks of age. (A) Paired-pulse ratios at
CA3-CA1 synapses from 2-week-old TASTPM are normal. (B) No
difference between TASTPM and wild-type spontaneous (s) or
miniature (m) EPSCs recorded from CA1 pyramidal neurons from
2-week-old TASTPM. (Wild-type: n = 5 animals; TASTPM, n = 5
animals.)
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Genome-wide expression analysis in
2- and 4-month-old mice shows
strong changes in synaptic genes
To investigate gene expression changes that might be asso-
ciated with the early synaptic changes, we accessed and
extended the relevant sections of a genome-wide micro-
array study that we have recently undertaken on this and
other transgenic mouse models that express human genes
for dementia (Matarin et al., 2015). Weighted Gene Co-
expression Network Analysis (WGCNA) was applied to
genes with highly variable expression at 2 and 4 months
to identify novel modules of genes with co-expression and
summarize the main enriched biological functions and mo-
lecular pathways that are disrupted at these early stages in
TASTPM mice. To increase the variability of gene expres-
sion and effectively bring in a dose-dependence to the ana-
lysis, we compared the wild-type gene expression to both
heterozygous and homozygous TASTPM mice.
The most variable genes (3000 genes) were determined
by their coefﬁcient of variation, without reference to pheno-
type or gene function. A dendrogram of the modules of
gene co-expression following WGCNA gave three modules
of genes that correlated signiﬁcantly with genotype: blue,
red and green-yellow in Fig. 5A. The red and blue modules
showed similarly high correlations with genotype (0.54,
P50.0005; 0.49, P50.001, respectively) but while syn-
aptic genes were included in both, they were more highly
enriched in the blue module. The four most signiﬁcant
Gene Ontology (GO) categories in this module (Table 1)
were designated ‘synaptic transmission’; ‘transmission of
nerve impulses’; ‘cell-cell signalling’ and ‘cell communica-
tion’ (each with FDR5 6  106) which ﬁts closely with
the main changes seen in the synaptic data above, particu-
larly changes in release probability and loss of spontaneous
action potentials. This module contained various genes
already associated with Alzheimer’s disease, as well as a
number of novel highly differentially expressed genes. The
differential expression of the genes belonging to the blue
module falling into the most signiﬁcant Gene Ontology cat-
egory are plotted in the heat map in Fig. 5B.
Expression of other example genes that are strongly dif-
ferentially expressed from early ages are shown in Fig. 5C
for hippocampus. In each case the microarray data were
validated using quantitative PCR and similar trends were
apparent. It should be noted that, in each case, expression
of either APPSwe (‘TAS10’) or PSEN1M146V (‘TPM’) alone,
had little effect on gene expression compared to wild-type
at 2 or 4 months (see www.mouseac.org; Matarin et al.,
2015), indicating that the changes observed are not due to
the expression of the individual transgenes. Of particular
interest we highlight genes, such as Bdnf, that have
frequently been associated with Alzheimer’s disease
(Lu et al., 2014) and other novel genes that warrant further
study as targets for early disease intervention or detection.
Some of these genes code for synaptic proteins such as the
active zone protein Rims3 (Wang and Sudhof 2003), which
has been associated with autism (Kumar et al., 2010) and
schizophrenia (Weidenhofer et al., 2009). Interestingly,
both Rims3 and Bdnf are only increased in expression in
heterozygous TASTPM mice by 4 months (although earlier
in homozygous TASTPM mice) and so may be a result of
the initial synaptic changes associated with rising amyloid-b
rather than a cause. In contrast, Faim2, which encodes an
anti-apoptotic protein (Somia et al., 1999) shows increased
expression already at 2 months, whereas Atf5, which has
been also suggested to be neuroprotective and to regulate
stem cell differentiation (Torres-Peraza et al., 2013) is
decreased in expression by this time. Another area of inter-
est is the early increase of endosomal pathway gene expres-
sion, such as Rab4, involved in recycling receptors from the
membrane to the endosome (Daro et al., 1996). Other
small GTPases have previously been linked to Alzheimer’s
disease, including an involvement of Rab6 in amyloid
precursor protein processing (McConlogue et al., 1996),
but Rab4a has not been previously implicated.
Discussion
Here we have presented a multidisciplinary study of the
earliest changes that occur in the TASTPM mouse model
of rising amyloid-b in the brain, allowing us to relate rises
of different amyloid-b peptides to the ﬁrst synaptic and
genetic changes in the hippocampus. We ﬁnd a pronounced
synaptic phenotype that begins as early as 2 months, when
amyloid-b levels are rising in the hippocampus but clearly
prior to the deposition of amyloid-b into plaques.
Moreover these changes precede the later dramatic rise in
amyloid-b42, generally suggested to be the most toxic form
(Walsh and Selkoe, 2007). The fact that plaque deposition
coincides with this rise in both amyloid-b levels and the
ratio of amyloid-b42 to other amyloid-b peptides, is consist-
ent with a recent study demonstrating that while amyloid-
b40 or amyloid-b42 can alone start to cause depositions in
neurites in cultures, the rate of deposition accelerates when
the two peptides are presented at a 1:1 ratio (Johnson
et al., 2013). However, the start of synaptic changes is
clearly not dependent on this. The changes feature an
almost complete absence of spontaneous action potential-
driven glutamate release from presynaptic glutamatergic
terminals and a concurrent increase in the probability of
successful glutamate release when action potentials are
evoked in the Schaffer collaterals or in the perforant path
to dentate gyrus. This change in release probability is, how-
ever, not uniform across all axons of the hippocampus, as
entorhinal cortical axons to CA1 neurons are unaffected
whereas ﬁeld recordings from CA3–CA3 axons and the
perforant path to CA3 axons suggest the opposite effect,
with decreased release probability.
The lack of detectable change at pre-weaning stages
when ratios of amyloid-b peptides are similar to those at
2 months and the overall levels are only slightly lower
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suggests that it is time of exposure, rather than concentra-
tion or ratio that is required. The question arises as to
which of these many changes is primary and which are
reactions to the initial change, either homeostatic or patho-
logical. Physiologically, amyloid-b is proposed to be
released during synaptic transmission by a process invol-
ving exocytosis, either in an activity-dependent or activity-
independent manner (Cirrito et al., 2008; Lundgren et al.,
2014). Once released, amyloid-b has been reported to in-
crease neurotransmitter release probability in normal ro-
dents (Abramov et al., 2009). Hence it seems likely that,
as amyloid-b levels begin to rise in TASTPM mice, the ﬁrst
effects might be increased release probability in the areas
where amyloid-b is highest. This suggests the hypothesis
that the decreases in spontaneous activity, seen both in
terms of spontaneously occurring action potentials and re-
lease in the CA3 region, might be a series of homeostatic
reactions to the initial increases in release probability in the
CA1 region. The speciﬁcity to particular pathways may
relate to localization of release of amyloid-b from
particular cell types or to susceptibility of particular types
of neurons to its effects. Exactly what effect these various
changes (increased probability of transmitter release and
decreased spontaneous activity in different regions) would
have on the overall activity of the hippocampus in vivo
cannot be assessed from a hippocampal slice. However,
neuronal hyperactivity has been reported in early
Alzheimer’s disease (see Stargardt et al., 2015 for a review).
It is interesting to note that, while multiple forms of
amyloid-b can be detected at these early stages in the
hippocampus of TASTPM mice, it is only well after synap-
tic changes have begun that the amyloid-b42:amyloid-b40
ratio reaches close to or indeed over 1:1. Recently
Dolev et al. (2013) reported that neuronal ﬁring frequencies
and patterns can alter the relative levels of different forms
of amyloid-b. They report that increased ﬁring frequencies
tended to increase amyloid-b40 relative to amyloid-b42. The
relative effects of loss of spontaneous activity versus
increased release probability could have different effects
depending on the environmental stimulus in different
Figure 5 Analysis of gene co-expression in hippocampus and the relation of specific synaptic modules of genes to genotype. (A)
Hierarchical clustering dendrogram for the most varying genes in homozygous TASTPM, heterozygous TASTPM mice and wild-type controls at 2
and 4 months old and equivalent module assignment colours. The modules that correlate with genotype are indicated with arrows. The y-axis
corresponds to the distance determined by the extent of topological overlap. (B) Heat map of genes involved in synaptic transmission (GO
category: GO0007268) identified by the DAVID database from the blue module of genes indicating how expression of these genes is increased or
decreased in homozygous and heterozygous TASTPM mice at 2 and 4 months old in the hippocampus compared to wild-type mice. Colours
represent the z-score of the expression level for each gene (red is high expression and green is low expression). (C) Further examples of
expression in early differentially expressed genes at 2 and 4 months old in heterozygous (HET) or homozygous (HOM) TASTPM mice. In all cases
two-way ANOVA indicated a main effect of genotype as indicated by stars. On the right of each graph the symbols represent the results of
quantitative PCR analysis in the same 4-month-old animals. The same trends are seen in all cases with significant differences indicated with
asterisks above the symbols. *P5 0.05; **P5 0.01; ***P5 0.001; ****P5 0.0001. Sample sizes: microarrays (WT/HET-TASTPM/HOM-TASTPM),
2 months: n = 11/4/4; 4 months: n = 12/4/4 mice. qPCR: n = 4 HOM-TASTPM mice and n = 4 wild-type mice. WT = wild-type.
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pathways and from moment to moment. Absence of spon-
taneous action potentials, such as we report here, could
result in an overall lower frequency of ﬁring in some
axons and, in turn, a higher amyloid-b42:amyloid-b40
ratio. Thus the increase in amyloid-b42 relative to amyl-
oid-b40 could also be a result of the chain of synaptic
changes, eventually leading to plaque deposition.
The present study conﬁrms that early changes in synaptic
transmission precede plaque deposition as reported previ-
ously (Jacobsen et al., 2006; D’Amelio et al., 2011; Tozzi
et al., 2015) although the exact nature of such changes
shows some differences between studies, probably reﬂecting
differences in recording conditions. The conﬁrmation of
such early synaptic change in different mouse models
of raised amyloid-b greatly strengthens the signiﬁcance of
these studies and is in agreement with the suggestion that in
Alzheimer’s disease, synaptic derailment is likely to occur
long before symptom onset and these studies would sug-
gest, also prior to plaque deposition.
The development of treatments targeting these early syn-
aptic changes could help to prevent a chain of events lead-
ing to on-going damage. To this end we have studied the
earliest gene expression changes that could be associated
with the synaptic phenotype. Although synaptic genes are
the most consistently affected functional group, in
TASTPM mice, these alterations in gene expression
frequently become detectable subsequent to the changes in
synaptic transmission and thus effects on synaptic gene
expression may be the result, rather than the cause, of
the synaptic changes. Presumably these reactive changes
contribute to the on-going efﬁcacy of cognitive function,
despite the substantial changes in the synaptic network
but may also contribute to the other behavioural changes
seen, such as an increase in aggression and anxiety and lack
of motivation (data not shown, but see Pugh et al., 2007),
which could relate to early symptoms reported in
Alzheimer’s disease (Robins Wahlin and Byrne 2011;
Ramakers et al., 2013). In contrast, there are also several
genes that are already considerably increased in expression
at 2 months old, even in the heterozygous TASTPM mice in
which the synaptic changes have been measured. Note that
these genes may be either contributing to, or protecting
against, the on-going changes we record and the possibility
of protective rather than harmful effects must be a consid-
eration in developing studies to test how such genes and
their products could be targeted to alter the early effects of
rising amyloid-b. In either case they suggest both novel
drug targets and also possible novel candidates for CSF
markers for the earliest stages of Alzheimer’s disease.
In summary, Alzheimer’s disease is a devastating condi-
tion. Understanding and detecting the earliest changes that
occur as amyloid-b begins to rise is the only possibility for
developing methods for controlling these changes and
preventing the on-going chain of events that lead to neuro-
degeneration and cognitive impairment. The present study
conﬁrms that changes in synaptic transmission precede
plaque deposition but also that they precede and may
even cause the increase in the ratio of amyloid-b42:amyl-
oid-b40, which is possibly responsible for triggering this
deposition and for further toxic change. Moreover, the
Table 1 Top four GO categories for the ‘Synaptic’ Blue module
Term Count % Genes Pop hits Fold-change Bonferroni Benjamini FDR
GO:0007268
‘synaptic transmission’
24 6.05 Gabrg1, Klk8, Dlgap1, Drd2, Pmch,
Nrxn3, Th, Snca, Tac1, Pdyn,
Slc17a7, Slc17a6, Gria2, Chrm3,
Chrm1, Grid2, Chrna4, Cartpt,
Sv2b, Slc5a7, Ppp3ca, Nrg1,
Chrna1, Chat
168 5.61 7.54  108 7.54  108 6.71  108
GO:0019226
‘transmission of
nerve impulse’
25 6.30 Drd2, Snca, Th, Tac1, Grid2, Chrna4,
Sv2b, Ppp3ca, Pou3f1, Nrg1,
Chrna1, Chat, Gabrg1, Dlgap1,
Nrxn3, Pmch, Pdyn, Gria2, Slc17a7,
Slc17a6, Chrm3, Chrm1, Klk8,
Cartpt, Slc5a7
212 4.63 1.55  106 7.76  107 1.38  106
GO:0007267
‘cell-cell signalling’
28 7.05 Drd2, Snca, Th, Tac1, Shh, Bdnf,
Grid2, Chrna4, Sv2b, Rapgef4,
Ppp3ca, Nrg1, Chrna1, Chat,
Gabrg1, Dlgap1, Klk8, Nrxn3,
Pmch, Dlgap2, Pdyn, Slc17a7,
Slc17a6, Gria2, Chrm3, Chrm1,
Cartpt, Slc5a7
276 3.99 3.52  106 1.17  106 3.13  106
GO:0007154
‘cell communication’
35 8.82 Drd2, Th, Snca, Itgb4, Tac1, Shh, Bdnf,
Grid2, Chrna4, Sv2b, Rapgef4,
Ppp3ca, Pou3f1, Chrna1, Nrg1,
Chat, Gabrg1, Pdyn, Dlgap1, Atg9b,
Klk8, Slc8a2, Nrxn3, Pmch, Dlgap2,
Nr4a2, Slc17a7, Slc17a6, Gria2,
Chrm3, Sfrp2, Chrm1, Avpr1a,
Cartpt, Slc5a7
428 3.21 6.38  106 1.60  106 5.68  106
FDR = false discovery rate.
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early changes in gene expression that accompany these
synaptic changes suggest a range of possible areas for
targeting drug development. The balance between regula-
tors of apoptosis may be key at the very start in avoiding
the advent of cell death or maintaining synapse number
(Sheng et al., 2012 for review). In contrast, synaptic gene
expression is affected early but probably as a result of the
initial changes in synaptic transmission, which may be
caused directly by increasing amyloid-b levels (Abramov
et al., 2009).
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